KMT2D and neoplasm: TP53 was the most prevalent co‐alteration occurring in tumours with CDKN2A/B alterations in 72% of patients (26/36), KRAS (72%, 23/32), EGFR (83%, 15/18), FLT1 (75%, 12/16), KEAP1 (65%, 11/17), KMT2D (70%, 14/20), SMARCA4 (71%, 10/14), STK11 (56%, 9/16), and in all tumours with AKT3 alterations (100%, 8/8).